Chordate Medical Holding AB Logo

Chordate Medical Holding AB

Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.

CMH | ST

Overview

Corporate Details

ISIN(s):
SE0021486131 (+1 more)
LEI:
549300R0GG2J3S0BFN79
Country:
Sweden
Address:
C/O Regus, 164 40 Kista

Description

Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia®, a CE-marked, drug-free neuromodulation treatment. The technology is indicated for the treatment of chronic migraine and chronic rhinitis. Ozilia® provides a non-pharmacological alternative to conventional medications, such as pills or injections, and is associated with minimal side effects. The company's business model is centered on building value through an extensive patent portfolio, clinical studies demonstrating efficacy, and establishing commercial success in selected markets with the goal of a future exit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chordate Medical Holding AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordate Medical Holding AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordate Medical Holding AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 Tommy Hedberg Other Other 2,917 11,668.00 SEK
2024-03-26 Anders Weilandt Other Buy 800,000 41,440.00 SEK
2024-03-26 Anders Weilandt Other Buy 200,000 10,540.00 SEK
2023-05-26 Anders Weilandt Other Buy 2,000,000 84,000.00 SEK
2023-05-26 Jan Hermansson Other Buy 750,000 31,500.00 SEK
2023-05-26 Nils Henrik Milton Rammer Other Other 350,000 14,700.00 SEK
2023-05-26 Caroline Brandberg Other Other 225,000 9,450.00 SEK
2023-05-26 Tommy Hedberg Other Buy 225,000 9,450.00 SEK
2023-01-09 Anders Weilandt Other Buy 3 2.10 SEK
2022-02-25 Anders Weilandt Other Buy 51,292 3,949,484.00 SEK

Peer Companies

Inmolecule Nanotech, S.A. Logo
Develops nanoparticles from plant compounds for biomedical and personal care products.
Spain
MLINA
Inotiv, Inc. Logo
A CRO providing nonclinical drug development services and research models.
United States of America
NOTV
IntegraGen Logo
Provides genomic services for cancer and rare diseases, translating research to practice.
France
ALINT
Intellia Therapeutics, Inc. Logo
A clinical-stage genome editing company developing therapeutics using CRISPR/Cas9.
United States of America
NTLA
InterDigital, Inc. Logo
An R&D company licensing foundational technologies for mobile, video, and AI.
United States of America
IDCC
IntoCell, Inc. Logo
Develops platform technologies for Antibody-Drug Conjugates (ADCs) for oncology.
South Korea
287840
Inventage Lab Inc. Logo
Biopharmaceutical company developing advanced drug delivery systems.
South Korea
389470
Investeko Spolka Akcyjna Logo
Specializes in environmental protection and sustainable business solutions.
Poland
IVE
IQVIA HOLDINGS INC. Logo
Provider of analytics, tech solutions, and clinical research for life sciences.
United States of America
IQV
Isofol Medical Logo
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
Sweden
ISOFOL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.